When treating refractory kidney cancer, clinicians prioritize regimens offering the most durable initial response. They argue against “saving” effective drugs for later, as disease progression is traumatic for patients and many never successfully receive subsequent lines of therapy. The goal is long-term disease control now, not preserving theoretical future options.

The investigator-led PLUTO trial found docetaxel chemotherapy provided a better overall survival benefit than lutetium in first-line mCRPC. This result directly confronts the common clinical bias against chemotherapy ("chemophobia"), proving that older treatments can still outperform newer targeted agents and should not be prematurely abandoned.

A key hypothesis for why docetaxel showed better overall survival than lutetium in the PLUTO trial is that patients treated with lutetium upfront may become unfit for subsequent chemotherapy. This highlights a critical factor in trial design: the planned therapeutic sequence and a patient's ability to receive later-line treatments significantly impact survival outcomes.

Clinicians may counsel patients towards therapies with lower efficacy if the dosing schedule is more convenient (e.g., quarterly). The rationale is that a lack of response is evident quickly, allowing a rapid pivot to another treatment without losing significant time or risking progression.

Despite his study showing an overall survival signal favoring docetaxel, lead author Dr. Kim Chi attributes this to crossover bias where patients avoided chemotherapy. He personally favors lutetium first due to its superior tolerability, contradicting the panel's majority opinion.

The PR21 trial showed better overall survival for docetaxel followed by Lutetium, despite similar progression-free survival. The likely reason is not drug superiority but patient behavior: a higher percentage of patients complete the second therapy when starting with chemo, highlighting how treatment fatigue significantly impacts survival.

Across dozens of clinical trials in metastatic castration-resistant prostate cancer (mCRPC) that have randomized an experimental agent against the chemotherapy docetaxel, Rucaparib is the first and only one to demonstrate a statistically significant improvement, highlighting the difficulty of improving on this standard of care.

Clinicians may be biased towards lutetium-PSMA because it causes significant PSA drops, which radium-223 does not. This observable metric may not reflect superior overall efficacy, as radium's survival benefit is proven and it may even have unique synergistic potential with drugs like enzalutamide through different biological pathways.

In the AMPLITUDE trial, only 16% of high-risk metastatic prostate cancer patients received docetaxel, despite it being allowed and indicated by disease characteristics. This suggests a real-world "chemophobia" or physician bias towards newer targeted therapies, even within a clinical trial setting.